GICS Sector : Healthcare
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
May -02
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
Apr -26
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Encore Wire Corporation - WIRE
Apr -17
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Apr -15
Could This Stock Be the Next Biotech Buyout?
Apr -13
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Apr -12
2 Biotech Stocks Driving the Nasdaq Today
Apr -11
Vertex Pharmaceuticals to Buy Alpine Immune in $4.9B Deal
Apr -11
Alpine Immune Sciences' 11.3% growth in Protein-based Immunotherapies is driven by increasing adoption in cancer treatment, rising demand for personalized medicine, and advancements in gene editing technologies like CRISPR. Additionally, strategic partnerships and collaborations are expanding the company's pipeline and accelerating clinical trials, further fueling growth.
A dual-acting fusion protein designed to block CD28 and CD80/86, which are key targets for autoimmune disease treatment.
A variant of the CD28 receptor that selectively binds to CD80/86, blocking the co-stimulatory signal and reducing T cell activation.
A novel class of immunomodulatory proteins that can be engineered to target specific immune cells and modulate their activity.
A novel class of immunomodulatory proteins that can be engineered to target specific immune cells and modulate their activity.
Alpine Immune Sciences, Inc. has a low threat of substitutes due to its unique and patented technology in the development of novel protein-based immunotherapies.
Alpine Immune Sciences, Inc. has a medium bargaining power of customers due to the presence of a few large pharmaceutical companies that can influence the market.
Alpine Immune Sciences, Inc. has a low bargaining power of suppliers due to its reliance on a few key suppliers for raw materials and equipment.
Alpine Immune Sciences, Inc. has a high threat of new entrants due to the growing interest in immunotherapy and the increasing number of biotech startups.
Alpine Immune Sciences, Inc. operates in a moderately competitive industry with a few established players, leading to a medium intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 2.93% |
| Debt Cost | 3.95% |
| Equity Weight | 97.07% |
| Equity Cost | 8.79% |
| WACC | 8.65% |
| Leverage | 3.02% |
Value: 0.3
Growth: 8.0
Quality: 8.8
Yield: 0.0
Momentum: 10.0
Volatility: 1.7
1-Year Total Return ->
Value: 6.0
Growth: 3.3
Quality: 4.1
Yield: 0.0
Momentum: 10.0
Volatility: 2.7
1-Year Total Return ->
Value: 1.5
Growth: 8.4
Quality: 8.5
Yield: 0.0
Momentum: 3.0
Volatility: 4.0
1-Year Total Return ->
Value: 7.1
Growth: 5.4
Quality: 7.2
Yield: 0.0
Momentum: 2.5
Volatility: 1.3
1-Year Total Return ->
Value: 6.0
Growth: 5.7
Quality: 5.0
Yield: 0.0
Momentum: 3.0
Volatility: 4.0
1-Year Total Return ->
Value: 6.0
Growth: 6.6
Quality: 4.0
Yield: 0.0
Momentum: 5.0
Volatility: 1.0
1-Year Total Return ->